Nicotinamide Riboside

Phase 3Small molecule

UUniversity of Oklahoma

Nicotinamide Riboside is one of 246 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

245

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Heart FailureActive, not recruiting

Peripheral Artery DiseaseActive, not recruiting

COVID-19Active, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Mild Cognitive ImpairmentCompleted

Ataxia-TelangiectasiaActive, not recruiting

Vascular DiseaseActive, not recruiting

Cognitive ImpairmentPhase 1

Active, not recruiting

Peripheral NeuropathyPhase 2

Active, not recruiting

Heart FailurePhase 1

Active, not recruiting

Peripheral Artery DiseasePhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Mild Cognitive ImpairmentPhase 1

Completed

Ataxia-TelangiectasiaPreclinical

Active, not recruiting

Vascular DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Nicotinamide Riboside

UUniversity of Oklahoma

Phase 3

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Singulair

AstraZeneca

Preclinical

1 4

Benadryl

PParkedale

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Conventional

PPopulation Health Research Institute

Preclinical

1 7

Blood Taken

HHospices Civils de Lyon

Preclinical

1 8

Selenium

SSWOG Cancer Research Network

Preclinical

1 9

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 10

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Allogeneic Hematopoietic Cell Transplant

NCT04332341

Q1 2027

Phase 2Recruiting

Idiopathic Pulmonary Fibrosis

NCT06567717

Q3 2027

Phase 1Recruiting

Vascular Disease

NCT06280482

Q4 2027

Post-ApprovalRecruiting

Aging

NCT05483465

Clinical

Trials by Indication[1]

Nicotinamide3 trials

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

Completed·JJohns Hopkins University·Phase 2·NCT03912220·45 enrolled

Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)

Completed·UUniversity of Florida·Phase 1·NCT04112043·147 enrolled

The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics

Terminated·MMclean Hospital·Phase 4·NCT03151707·11 enrolled

Peripheral Neuropathy2 trials

NR in Chemo-induced Peripheral Neuropathy

Terminated·—·Phase 2·NCT03642990·5 enrolled

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

Active, not recruiting·—·Phase 2·NCT04112641·48 enrolled

Arterial Stiffness2 trials

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

Recruiting·DDouglas Seals·Phase 2·NCT03821623·118 enrolled

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04040959·118 enrolled

COVID-191 trial

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT04818216·28 enrolled

Ataxia-telangiectasia1 trial

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside

Unknown status·TThe University of Queensland·N/A·NCT06324877·10 enrolled

9 more indications

Idiopathic Pulmonary Fibrosis1 trial

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

Recruiting·—·Phase 2·NCT06567717·60 enrolled

Peripheral Artery Disease1 trial

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

Completed·NNorthwestern University·Phase 3·NCT03743636·90 enrolled

Hospitalized Patients1 trial

Nicotinamide Riboside in Hospitalized Patients

Completed·OOslo University Hospital·Phase 1/2·NCT04110028·57 enrolled

Vascular Disease1 trial

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 1·NCT06280482·15 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Recruiting·—·Phase 1·NCT04332341·20 enrolled

Aging1 trial

The Effect of NAD Supplementation on Brain Vascular Health in Aging

Recruiting·UUniversity of Oklahoma·Phase 4·NCT05483465·214 enrolled

Heart Failure1 trial

Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

Active, not recruiting·UUniversity of Washington·Phase 1·NCT04528004·32 enrolled

Mild Cognitive Impairment1 trial

Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia

Completed·MMclean Hospital·Phase 1·NCT04430517·21 enrolled

Unspecified1 trial

NAD Supplementation and Vascular Health in PAD

Completed·UUniversity of Oklahoma·Phase 1/2·NCT06534944·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Nicotinamide Riboside. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicotinamide Riboside compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicotinamide Riboside. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Oklahoma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Oklahoma

Nicotinamide Riboside

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Nicotinamide3 trials

Peripheral Neuropathy2 trials

Arterial Stiffness2 trials

COVID-191 trial

Ataxia-telangiectasia1 trial

Idiopathic Pulmonary Fibrosis1 trial

Peripheral Artery Disease1 trial

Hospitalized Patients1 trial

Vascular Disease1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Aging1 trial

Heart Failure1 trial

Mild Cognitive Impairment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News